# Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

> **NCT03961698** · PHASE2 · UNKNOWN · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 91 (actual)

## Conditions studied

- Breast Cancer
- Renal Cell Carcinoma

## Interventions

- **DRUG:** IPI-549 (eganelisib)
- **DRUG:** Atezolizumab
- **DRUG:** nab-paclitaxel
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03961698
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-17
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961698, "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03961698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*